COVID-19 outcomes among individuals with common variable immunodeficiency FrontiersIn FrontImmunol koebenhavns_uni COVID19 coronavirus covid immunodeficiency
By Tarun Sai LomteOct 17 2022Reviewed by Danielle Ellis, B.Sc. In a recent study published in the Frontiers in Immunology, researchers evaluated the outcomes of coronavirus disease 2019 in individuals with common variable immunodeficiency .
By contrast, genetic variants affecting innate immunity are associated with a higher risk of fulminant COVID-19. Moreover, reported outcomes have varied among IEI groups. Preliminary case reports suggested that agammaglobulinemia patients may have better COVID-19 outcomes than those with CVID, albeit it has been challenged.
The research team included individuals aged 18 or above living in Denmark at study inclusion who were registered thrice or more with D830, D838, or D839 International Classification of Diseases, Tenth Revision codes. The study inclusion date was March 1, 2020, or when the subject was registered with the specified ICD-10 codes, whichever was later. Eight controls from the general population were randomly matched to each patient.
The time to the first SARS-CoV-2-positive test was slightly different between the two cohorts. The frequency of COVID-19 testing was consistently different between the two groups throughout the study. CVID individuals had elevated testing frequencies earlier in the study, while controls had increased testing during March-August 2021. However, the testing frequencies differed marginally later in the study.